711 related articles for article (PubMed ID: 27980047)
1. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
[TBL] [Abstract][Full Text] [Related]
2. Site-Specific Immuno-PET Tracer to Image PD-L1.
Wissler HL; Ehlerding EB; Lyu Z; Zhao Y; Zhang S; Eshraghi A; Buuh ZY; McGuth JC; Guan Y; Engle JW; Bartlett SJ; Voelz VA; Cai W; Wang RE
Mol Pharm; 2019 May; 16(5):2028-2036. PubMed ID: 30875232
[TBL] [Abstract][Full Text] [Related]
3. A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues.
Natarajan A; Patel CB; Ramakrishnan S; Panesar PS; Long SR; Gambhir SS
Clin Cancer Res; 2019 Mar; 25(6):1774-1785. PubMed ID: 30373750
[TBL] [Abstract][Full Text] [Related]
4. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.
Natarajan A; Mayer AT; Xu L; Reeves RE; Gano J; Gambhir SS
Bioconjug Chem; 2015 Oct; 26(10):2062-9. PubMed ID: 26307602
[TBL] [Abstract][Full Text] [Related]
5. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
[TBL] [Abstract][Full Text] [Related]
6. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
[TBL] [Abstract][Full Text] [Related]
7. Immuno-PET Imaging of
Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Imaging of the Programmed Death Ligand 1 by
González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
[TBL] [Abstract][Full Text] [Related]
9. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X
Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
11. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
12. Sensitive Positron Emission Tomography Imaging of PD-L1 Expression in Human Breast and Lung Carcinoma Xenografts Using the Radiometalated Peptide Ga-68-TRAP-WL12.
Quigley NG; Steiger K; Färber SF; Richter F; Weichert W; Notni J
Mol Pharm; 2024 Apr; 21(4):1827-1837. PubMed ID: 38291706
[TBL] [Abstract][Full Text] [Related]
13. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
[TBL] [Abstract][Full Text] [Related]
14. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
15. Preclinical development of novel PD-L1 tracers and first-in-human study of [
Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
[TBL] [Abstract][Full Text] [Related]
17. A Novel Small Cyclic Peptide-Based
Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Biologic Evaluation of a Novel
Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation and pilot clinical study of [
Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
[TBL] [Abstract][Full Text] [Related]
20. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
[No Abstract] [Full Text] [Related]
[Next] [New Search]
